MDA 2024: Planned Phase 3b trial aims to show NurOwn's efficacy
Mar 6, 2024 · A pivotal, Phase 3b clinical trial is planned to test the cell-based therapy NurOwn (debamestrocel) in people with amyotrophic lateral sclerosis (ALS), the treatment’s developer, Brainstorm Cell Therapeutics, announced.. The study’s design, based on positive findings from a previous Phase 3 trial in patients with less advanced disease, is under U.S. Food and Drug Administration (FDA) review.
Phase 3 trial of oral pridopidine in treating ALS likely this year
Jan 29, 2024 · The HEALEY ALS (NCT04297683) platform trial is designed to simultaneously evaluate multiple experimental ALS treatments against a shared placebo group. It is being led by researchers at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital in Boston. The Phase 2/3 pridopidine arm (NCT04615923) enrolled 163 adults with clinically possible, probable, or definite ALS, whose ...
News Archives - ALS News Today
MN-166 may slow ALS progression over year, trial data suggest. MN-166 (ibudilast), an investigational oral treatment for amyotrophic lateral sclerosis (ALS), appears to slow disease progression over up to one year of use, according to an analysis of data in …
PrimeC in ALS patients shown to extend complication-free survival
Mar 4, 2024 · The new data comes from the PARADIGM Phase 2b study (NCT05357950), a fully enrolled clinical trial that’s testing oral PrimeC against a placebo in 68 adults with ALS. Participants had experienced their first symptoms within the prior 30 months and could continue to receive their standard ALS medications.. These findings come shortly after positive top-line data from the PARADIGM trial that ...
ALS News Today Home | ALS News Today
Dec 4, 2024 · Study finds early-life events may be environmental risk factors for ALS. People with amyotrophic lateral sclerosis (ALS) are more likely than those without the neurodegenerative disease to have grown up in rural areas, have younger parents, and have lower levels of education, a new study found.
Amyotrophic Lateral Sclerosis (ALS) Symptoms – ALS News Today
Feb 6, 2023 · Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which worsening muscle weakness leads to movement problems and other symptoms such as trouble swallowing, speaking, and breathing. Patients also can experience digestive issues, mental health problems, and changes in behavior.
Types of Amyotrophic Lateral Sclerosis (ALS) – ALS News Today
Mar 8, 2023 · Amyotrophic lateral sclerosis (ALS) is a progressive disorder marked by muscle weakness and atrophy (wasting), which usually is mild to start and affects only one body part, then becomes more severe and gradually spreads to impact the whole body. It is classified based on the presence or absence of a family history, as well as …
The stages of amyotrophic lateral sclerosis (ALS) - ALS News Today
Jun 13, 2024 · Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder marked by progressively worsening stages of progression.People with ALS experience muscle weakness and neurological dysfunction, but initial symptoms are typically mild and affect only one part of the body. As the disease becomes more and more severe, these issues gradually spread to the entire body, affecting a range of ...
Digestive Symptoms - ALS News Today
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the death of motor neurons — the nerve cells that control muscle movement. The primary symptoms of ALS include muscle weakness, tremors, and cramps. However, patients may experience other symptoms — including digestive problems that may contribute to disease progression — which they may be ...
Amyotrophic Lateral Sclerosis (ALS) Treatment - ALS News Today
Apr 11, 2024 · A number of treatment options exist for amyotrophic lateral sclerosis (ALS), a disease marked by the progressive loss of motor neurons — specialized nerve cells that control muscle movements — and symptoms like muscle weakness and wasting.